Risk Partners Life Sciences Roundtable 2024, thank you very much! Already for the 26.06.2025 >

Contact us

Atrialis GmbH - experts in clinical trial insurance &
Risk Partners will play in the same team in future.

LifeSciences - Leading risk concepts for leading science!Β 

This has been our guiding principle for many years in advising innovative companies in the fields of biotechnology, pharmaceuticals and medical products on risk issues and providing them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insurance of a clinical trial).

Together with my team at Risk Partners GmbH, we want to emphasize our focus, passion and expertise in insurance for the life sciences industry and support even more medical research initiatives with special insurance concepts for clinical trials and subject coverage. The same applies to our colleagues at Atrialis GmbH: experts in clinical trials, which has been one of the leading companies in the life sciences sector since 2007.

In order to be able to offer our joint target customers an even better service and range of products, we have notarized the merger of our companies and look forward to jointly providing market-leading service and risk transfer to life science customers in the future. From the foundation to the NASDAQ IPO - accompanied by life sciences insurance specialists.

Also read our other blog posts

Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
April 19, 2024
Life Sciences

Finance Day 2023

Growth capital for biotechnology: Yesterday, today, tomorrow! A few days ago, Jutta Zaglauer and Florian Eckstein from our team attended the Finance Day 2023 on the occasion of the 25th anniversary of biotechnology at the IZB - Innovation and Startup Center for Biotechnology. The event offered an exciting exchange and insights into current financing and capital market issues of biotechnology companies. As an experienced specialist insurance broker for the areas of life sciences, venture capital and IPOs, all three cornerstones of our "magic expertise triangle" were part of the exciting agenda. It was also interesting to discuss the importance of customized

Read more "
November 6, 2023
Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TÜV association among 501 companies with more than ten employees. According to the TÜV

Read more "
October 22, 2023
Your question has not been answered?
We will be happy to advise you in a free initial consultation.
Get advice now